{'fraction_non_alphanumeric': 0.041304347826086954, 'fraction_numerical': 0.008695652173913044, 'mean_word_length': 4.75625, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Why adefovir is not yet available in Canada.

The introduction of lamivudine for the management of chronic hepatitis B virus (HBV) infection heralded a new era in the management of the disease. Until then, the only available therapy was interferon-alpha (IFN-α), which was expensive and difficult to take. It required three injections a week for four months to two years for some forms of HBV. IFN-α was able to induce a response in a small proportion of patients. In hepatitis B e antigen (HBeAg)-positive patients, seroconversion from HBeAg to the antibody for HBe (anti-HBe) occurred in just over 30% of treated patients (1,2). Alanine aminotransferase (ALT) normalized and HBV DNA became undetectable in serum using the insensitive assays at the time. In the anti-HBe-positive patients, the durable response of therapy was appoximately 20%, again using the insensitive solution hybridization assay for HBV DNA (3–5).